The Impact of Camostat Mesilate on COVID-19 Infection

2020-03-31 04:04:35 | BioPortfolio


SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease presentation which has now been named COVID-19. The virus has subsequently spread throughout the world and was declared a pandemic by the World Health Organisation on 11th March 2020. As of 18 March 2020, there are 198,193 number of confirmed cases with an estimated case-fatality of 3%. There is no approved therapy for COVID-19 and the current standard of care is supportive treatment.

SARS-CoV-2 exploits the cell entry receptor protein angiotensin converting enzyme II (ACE-2) to access and infect human cells. The interaction between ACE2 and the spike protein is not in the active site. This process requires the serine protease TMPRSS2. Camostat Mesilate is a potent serine protease inhibitor. Utilizing research on severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 cell entry mechanism, it has been demonstrated that SARS-CoV-2 cellular entry can be blocked by camostat mesilate. In mice, camostat mesilate dosed at concentrations similar to the clinically achievable concentration in humans reduced mortality following SARS-CoV infection from 100% to 30-35%.

Study Design


Corona Virus Infection


Camostat Mesilate, Placebo oral tablet


Department of Infectious Diseases


Not yet recruiting


University of Aarhus

Results (where available)

View Results


Published on BioPortfolio: 2020-03-31T04:04:35-0400

Clinical Trials [5210 Associated Clinical Trials listed on BioPortfolio]

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of colchicine in adult patients diagnosed with COVID-19 ...

Awareness Between Pregnant Women Regarding Corona

Corona virus is known as covid 19 And is transmitted through droplet infection

Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol

To investigate the safety, tolerance, dynamic percolation model of single dose usage pazufloxacin mesilate ear drops for patients with acute suppurative otitis media or chronic suppurative...

Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization

This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. E...

PubMed Articles [13390 Associated PubMed Articles listed on BioPortfolio]

Oral Human Papillomavirus: a multisite infection.

The Human Papillomavirus (HPV) has different strategies for persist in the cells. This characteristic has led us to consider the presence of the virus in tissues of the oral cavity that had no clinica...

Corona Virus Disease 2019, a growing threat to children?

The controversial natural history of oral Herpes Simplex Virus Type 1 infection.

The natural history of oral Herpes Simplex virus Type-1 (HSV-1) infection in the immunocompetent host is complex and rich in controversial phenomena. Namely, the role of unapparent transmission in pri...

Detection of Epstein-Barr virus genome in oral cavity squamous cell carcinoma samples of russian patients.

Oral cavity squamous cell carcinoma (OC-SCC) is the most common and aggressive malignancy of the oral cavity. Recent studies have revealed infections with human papilloma virus (HPV) as an additional ...

Evaluation of IL-2, IL-10, IL-4 and ɤ-interferon levels in the oral fluids of patients with hepatitis C, B and HIV.

Oral fluid cytokine levels can vary considerably during the onset of Inflammatory Periodontitis (IP) especially in people with hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficien...

Medical and Biotech [MESH] Definitions

A highly contagious parvovirus infection in mink, caused by MINK ENTERITIS VIRUS or the closely related FELINE PANLEUKOPENIA VIRUS or CANINE PARVOVIRUS. Transmission usually occurs by the fecal/oral route.

A phenomenon in which infection by a first virus results in resistance of cells or tissues to infection by a second, unrelated virus.

Epithelial hyperplasia of the oral mucosa associated with Epstein-Barr virus (HERPESVIRUS 4, HUMAN) and found almost exclusively in persons with HIV infection. The lesion consists of a white patch that is often corrugated or hairy.

Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.

A strain of HEPATITIS A VIRUS which causes hepatitis in humans. The virus replicates in hepatocytes and is presumed to reach the intestine via the bile duct. Transmission occurs by the fecal-oral route.

More From BioPortfolio on "The Impact of Camostat Mesilate on COVID-19 Infection"

Quick Search

Searches Linking to this Trial